Dasatinib Inhibits Lung Cancer Cell Growth and Patient Derived Tumor Growth in Mice by Targeting LIMK1

Lung cancer is a leading cause cancer-related death with diversity. A promising approach to meet the need for improved cancer treatment is drug repurposing. Dasatinib, a second generation of tyrosine kinase inhibitors (TKIs), is a potent treatment agent for chronic myeloid leukemia (CML) approved by...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Man, Tian, Jie, Wang, Rui, Song, Mengqiu, Zhao, Ran, Chen, Hanyong, Liu, Kangdong, Shim, Jung-Hyun, Zhu, Feng, Dong, Zigang, Lee, Mee-Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746816/
https://www.ncbi.nlm.nih.gov/pubmed/33344441
http://dx.doi.org/10.3389/fcell.2020.556532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746816/
https://www.ncbi.nlm.nih.gov/pubmed/33344441
http://dx.doi.org/10.3389/fcell.2020.556532

Ejemplares similares